Were you looking for information on Bevacizumab? Bevacizum is a common misspelling of bevacizumab.
Bevacizumab (Avastin®) is a prescription drug used in the treatment of certain types of cancer -- specifically, colon, rectal, and non-squamous, non-small cell lung cancer.
In late 2010, the United States Food and Drug Administration (FDA) recommended that bevacizumab's breast cancer approval be removed. Studies have not shown the drug to increase survival in people with breast cancer, and there is not sufficient benefit to outweigh the risks.
This action does not affect bevacizumab's approval for other uses. Healthcare providers may still use bevacizumab to treat breast cancer, although they will be doing so in an "off-label" fashion.
The drug discourages the growth of new blood vessels by binding to and inhibiting a specific kind of protein. As a result, the cancer is essentially "starved" of its blood supply. Bevacizumab is given by injection at your healthcare provider's office. Side effects can include diarrhea, nausea, and fatigue.
(Click Bevacizumab to read the complete eMedTV article, which examines in detail how the drug works to fight cancer, additional side effects, what to tell your healthcare provider before taking it, and more.)